NEGATIVE INOTROPIC EFFECT OF PLATELET-ACTIVATING FACTOR ON HUMAN MYOCARDIUM - A PHARMACOLOGICAL STUDY
- 1 December 1987
- journal article
- research article
- Vol. 243 (3) , 834-839
- https://doi.org/10.1016/s0022-3565(25)39298-0
Abstract
Because platelet-activating factor (PAF) has prominent depressant effects on cardiac contractility in various mammalian species, we assessed the negative inotropic effect of PAF on noncoronary perfused human right atrial pectinate muscles paced at constant rate. We found that PAF is a potent negative inotropic agent (EC50 .apprxeq. 160 pM), whose action is unmodified by atropine, indomethacin and the leukotriene receptor antagonist compound FPL 55712. The negative inotropic effect of PAF was, however, antagonized by drugs known to inhibit PAF-induced platelet aggregation: the order of relative potency was SRI 63-441 > CV-3988 > alprazolam .gtoreq. triazolam; i.e., the same order in which these compounds antagonize the effects of PAF on platelets. Thus, the potent negative inotropic effect of PAF on human myocardium is independent of coronary flow changes, involves neither cholinergic mechanisms nor arachidonate metabolites and is probably mediated by specific receptors.This publication has 3 references indexed in Scilit:
- Electrophysiological effects of acetyl glyceryl ether phosphorylcholine on cardiac tissues: comparison with lysophosphatidylcholine and long chain acyl carnitineBritish Journal of Pharmacology, 1986
- Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxiaBiochemical and Biophysical Research Communications, 1984
- The cardiac effects of prostaglandins and their modification by the prostaglandin antagonist N-0164.The Journal of Pharmacology and Experimental Therapeutics, 1980